Alluvi, initially dubbed LY3414901, represents a exciting advancement in weight management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receiver agonist shows remarkable effectiveness in early trial data, with impressive weight loss obs